Solid Tumor Clinical Trial
Official title:
A Phase I Clinical Study To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Patients With Advanced or Metastatic Solid Tumors
This Phase1, open-label and dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX07 administered as a single-agent by IV infusion every 3 weeks to patients with locally advanced or metastatic solid malignancies, who have failed or are intolerant to standard therapy, or for whom no standard therapy is available.
Status | Not yet recruiting |
Enrollment | 24 |
Est. completion date | February 28, 2024 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF); - Aged = 18 years, = 75 years; - Patients must have histologically confirmed malignant solid tumors which are advanced or metastatic, have failed prior standard treatment, and be intolerant or ineligible for standard therapy; - Measurable disease according to RECIST Version 1.1; - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; - Expected survival 12 weeks; - Adequate organ function; - For fertile female subjects, the pregnancy test must be negative within 7 days before the first dose; Exclusion Criteria: - Prior anti-EGFR (including EGFR ADC) monoclonal antibody therapy; - A history of other malignancies within two years, except for cured Localized tumor; - Participants with any prior allogeneic solid organ or bone marrow transplantations; - Symptomatic brain or meningeal metastases (unless the patient has been on > treatment for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial administration, and tumor-related clinical symptoms are stable); - Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated drainage; - Active clinical severe infection; |
Country | Name | City | State |
---|---|---|---|
China | Fudan University shanghai cancer center | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Henlius Biotech |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Incidence of Treatment-Related Adverse Events | 2 years | ||
Primary | The proportion of patients experiencing dose limiting toxicity (DLT) events | from first dose to the end of Cycle 1 (each cycle is 21 days) | ||
Primary | The maximum tolerated dose (MTD) | from first dose to the end of Cycle 1 (each cycle is 21 days) | ||
Secondary | Peak plasma concentration (Cmax) of HLX07 | 2 years | ||
Secondary | Time to peak (Tmax) of HLX07 | 2 years | ||
Secondary | Area under the concentration-time curve (AUC) of HLX07 | 2 years | ||
Secondary | Elimination half-life (t1/2) of HLX07 | 2 years | ||
Secondary | Clearance (CL) of HLX07 | 2 years | ||
Secondary | Volume of distribution (Vz) of HLX07 | 2 years | ||
Secondary | Accumulation Index (Rac) of HLX07 | 2 years | ||
Secondary | Incidence of treatment-emergent anti-drug antibodies (ADA) | 2 years | ||
Secondary | Objective response rate (ORR) | 2 years | ||
Secondary | Disease control rate (DCR) | 2 years | ||
Secondary | Duration of response (DOR) | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |